Silo pharma inc SILO.US Overview Analysis
SILO AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.
SILO Current Performance
0.60%
Silo pharma inc
1.31%
Avg of Sector
0.58%
S&P500
Top 10 High Relevance to SILO
- AMIX Autonomix medical incValue -Trend 3Swing Trading 2Whale Interest 1Dividend 1See more
SILO Profile
Silo Pharma, Inc. is a developmental stage biopharmaceutical company. It is focused on developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It is engaged in acquiring and/or developing intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin, and the potential benefits they may have in certain cases involving depression, mental health issues and neurological disorders. Its lead program, SPC-15, is an intranasal treatment targeting post-traumatic stress disorder and stress-induced anxiety disorders. Its SP-26 is a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. Its two preclinical programs are SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis.